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Abstract
Background: Only half of those living with Alzheimer’s disease in France are currently diagnosed, and only one
patient in three is supported during the early stages of dementia. This study aims to evaluate three cognitive tests
for their predictive ability to diagnose mild cognitive impairments and Alzheimer’s disease and related disorders.
For people aged 65 years or over, presenting with a memory complaint, these tests can be performed easily during
a preventative consultation.
Method/design: The EVATEM (évaluation des troubles de l’équilibre et de la mémoire (evaluation of balance and memory
problems)) cohort study was designed to prospectively assess the predictive value of tests for the diagnosis of mild
cognitive impairments and Alzheimer’s disease in elderly subjects aged 65 years or over. Subjects were recruited from
three health examination centers that are part of the French health insurance system. If a memory complaint was
identified (using a dedicated questionnaire), the five-word test, the cognitive disorders examination test and the verbal
fluency test were administered during a preventative consultation. A memory consultation was performed at a University
Hospital to diagnosis any potential cognitive disorder and a one-year follow-up consultation was also scheduled. We
recorded 2041 cases of memory complaint at our Health Examination Centers. Cognitive tests were refused by 33.6% of
people who had a memory complaint. The number of subjects sent to a University Hospital memory consultation was
832 and 74.5% of them completed this consultation. The study population therefore includes 620 subjects.
Discussion: Tests for the early diagnosis of a mild cognitive impairment or Alzheimer’s disease and related disorders
should be used in centers dedicated to disease prevention. These should guide subjects with memory impairment to
full memory consultations at hospitals and improve the access to early medical and behavioral support.
Trial registration: ClinicalTrials.gov: NCT01316562
Keywords: Early diagnosis, Alzheimer’s disease, Memory complaint, Mild cognitive impairment
Background
In 2011, an estimated 5.4 million Americans were living
with Alzheimer’s disease (AD); this number is expected
to grow to 7.7 million by 2030. In France, AD affects
about 800,000 people over the age of 75 [1]. The patho-
physiological process of Alzheimer’s disease is known to
begin several years before the onset of cognitive
symptoms. This “pre-clinical” stage is regarded as the
most efficient stage for therapeutic intervention but it is
still an active domain of research [2,3]. Although the
benefit of early diagnosis is still debated, early identifica-
tion of a cognitive impairment could lead to earlier
treatment, better care management and improved un-
derstanding of the disease [4,5]. Being able to inform the
patient and their family about the disease, at a time
when the patient can still fully comprehend their illness,
may ensure a better long-term quality of life for patients
* Correspondence: Christiane.nitenberg@cpam-rhone.cnamts.fr
1Centre d’Examens de Santé de la CPAM du Rhône, Lyon, France
Full list of author information is available at the end of the article
© 2013 Vannier-Nitenberg et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Vannier-Nitenberg et al. BMC Geriatrics 2013, 13:55
http://www.biomedcentral.com/1471-2318/13/55
and caregivers as well as help to limit crisis situations.
Only half of those living with AD in France are currently
diagnosed, and only one patient in three is supported
during the early stages of dementia [6]. According to the
PAQUID cohort study [7], the average Mini-Mental
State Examination (MMSE) [8] score at the diagnosis of
dementia is approximately 19 (maximum score possible:
30). This score corresponds to a moderate stage of the
disease. The average time taken to diagnose dementia in
France is estimated to be 24 months; this is relatively
long as the average time taken in Europe is estimated at
20 months and, in Germany, 10 months [9]. Cognitive
impairment diagnoses are performed by specialized
multi-disciplinary teams during memory consultations.
Diagnoses carried out in France since 2009 are listed in
the Alzheimer National Bank (created under the 34th
measure of the National Alzheimer’s Plan (2008–2012)).
Of the 118,776 patients observed in 320 memory clinics
(MC) during 2010, Mild Cognitive Impairment (MCI)
was diagnosed in 8.4% of the cases [10]. The health ex-
aminations centers (HEC) perform 550,000 periodic ex-
aminations dedicated to screening, prevention and
health education each year; people over 60 years old rep-
resent about 20% of those receiving periodic examina-
tions. Senior health examinations [11,12], set up in 2006,
focus on screening for fall risk without particular atten-
tion to memory complaints.
A study of 1020 people aged 60 years or over, at six
HEC, found a prevalence of memory complaints in
35.1% of cases [13,14]. A resulting 12.3% of the patients
were sent to MC following neuropsychological tests such
as the MMSE. These types of assessments are difficult to
perform routinely during a preventive consultation.
Studies have therefore been set up to identify simple
tests, feasible in consultation at HEC with elderly pa-
tients expressing a memory complaint, that have good
predictive power to diagnose MCI [15,16,17,18] and AD
and related diseases.
The EVATEM (évaluation des Troubles de l’équilibre
et de la mémoire (evaluation of balance and memory
problems)) study aims to evaluate the predictive values
(PV) of three cognitive tests for the diagnosis of MCI
and AD and related disorders in community-dwelling
elderly people. The secondary objective is to assess the
relationship between falls and cognitive impairments.
Methods/design
Study design
This is a prospective multicenter cohort study with a
one-year follow-up. Tests were carried out at two types
of medical organizations: HEC and MC. HEC are struc-
tures belonging to the French health insurance system
which offers check-ups and screening for the prevention
of health conditions, health education and actions, and
chronic disease support. This is a free check-up and pri-
ority is given to frail or vulnerable people. MC (as de-
fined by the circular issued by the Direction Générale de
l’Offre de Soins (DHOS) (general directorate for
healthcare provision) on 16th April 2002) offer consulta-
tions and day hospitalizations which are dedicated to
medical diagnostics, follow-up and nursing (treatments
both with and without the administration of drugs). MC
are responsible for research on AD and related disor-
ders, participate in academic training and coordinate an
interregional plan for local memory consultations.
The three HEC which participated in the EVATEM
study are located in three French cities: Lyon Angers
and Saint-Etienne. The diagnostics were performed
through three MC in the academic hospitals of these
three cities. The study is composed of several steps
(Figure 1). Patients with a memory impairment were
identified at HEC using questionnaires and cognitive
tests during periodic health examination at T0. Memory
consultations to diagnose MCI and AD and related dis-
orders were carried out at MC according to a standard-
ized neuropsychological evaluation and complementary
exam at T0. A one-year follow-up exam, at T1, was
scheduled for each of the patients.
Ethical and legal considerations
All EVATEM subjects gave their informed consent to
participate in this study. Their participation or refusal
had no effect on the usual nursing performed at the
HEC. The study protocol has been reviewed and ap-
proved by an ethics committee CPP Sud-Est III (comité
de protection des personnes Sud-Est III (Persons protec-
tion comity of South-East III)) on the 7th of July 2009.
All procedures are in compliance with the Helsinki dec-
laration. Data processing is approved by the CNIL (com-
mission nationale de l’informatique et des libertés
(National Commission for Informatics and Liberties))
under n°1362516.
EVATEM study has been registered in the clinical
trials (Current Controlled Trials NCT01316562).
Population
Subjects were selected during free periodic health exam-
inations in one of the three health examinations centers
that participated in this study. These HEC were located
to the cities of Lyon, Angers and Saint-Etienne.
Patients could be included if they were 65 years of age or
older, lived at home or in a non-medical institution,
volunteered to participate to a periodic health examination
and if a memory impairment concern was identified (either
by the patient themselves or by a member of their family).
Patients were excluded from the study if they had demen-
tia, an inadequate level in French language ability, to a sen-
sory deficiency which would compromise their evaluation.
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Sample size
We calculated the required sample size need to detect
an expected sensitivity and specificity of 0.9 with the
cognitive tests used in the HEC.
We set the minimum acceptable lower 95% confidence
limit at 0.75, with a 0.95 probability.
Using the table of Flahault et al. 70 confirmed cases
were required [19]. The number of controls required
was calculated to be 513 with the equation: N controls =
N cases [(1-P)/p] [19]; where p was the expected preva-
lence of MCI or AD and related disorders (we supposed
this to be 12% [13]). The total target sample size was
therefore 583.
We predicted the loss of subjects between examina-
tions in the HEC and the MC to be 30% and so aimed
to recruit 833 subjects. Actual recruitment was consist-
ent with these estimates.
Data collection
1. Senior health periodic examination at HEC
a. Socio-demographic data
Age, sex, marital status, address, economic
affluence and vulnerability level (evaluated with
the EPICES score, the individual index of
deprivation used at the HEC [20]) were recorded.
b. Clinical data
We recorded weight, height, the number of
different daily therapeutic groups attended,
psychotropic dose (established by asking the
patient or reading their last prescription),
autonomy (evaluated by testing four activities of
daily life [21]), and mood (evaluated using the
Mini-Geriatric Depression Scale (mini-GDS) [22]).
c. Para-clinical data
Data recorded included long sighted visual
acuteness (evaluated using the Monoyer scale), an
evaluation of balance and walking (using tests
such as the Timed Up and Go (TUG) [23] and
the imagined TUG), patient proprioception
sensitivity (measured using the diapason test),
and the results of the handgrip test, unipodal
position evaluation, chair rising, temporal analysis
of walking and posture analysis (at the HEC of
Lyon and Angers).
d. Memory complaint
A self-questionnaire composed of binary
questions (Q1) was used to assess memory at the
Health Examination Center
Identification of elderly subjects over 65 years old with an authenticated memory complaint 
Elderly subjects invited (by letter) to be included in the EVATEM study
Medical consultation
The three cognitive tests selected for the study are performed
Memory Clinic at University Hospital
Initial memory consultation (T0)
Neuropsychological, biological and medical check-up
One-year follow-up consultation (T1)
Neuropsychological and medical check-up
Figure 1 An outline of the steps in the EVATEM study.
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HEC Angers and Saint-Etienne. A questionnaire
(Q2) was carried out by the doctor at the HEC of
Lyon (Table 1). At least one positive answer to
the questionnaire was required for the subject to
be included in the study.
e. Cognitive testing performed
The EVATEM study assessed Dubois’ five-word
test [24], the cognitive disorders examination test
(CODEX) [25,26] and the verbal fluency test [27].
These tests were chosen as they assess verbal
memory, temporal and spatial orientation and
executive function but are straightforward and
rapid.
Dubois’ five-word test is an episodic memory test
where subjects are asked to learn five words
belonging to different semantic groups and
lacking phonetic similarity (for example: beverage,
cooking tool, vehicular, building and insect) with
control of the encoding. The test is built in such
a way that it enables differentiation between
symptoms of hippocampus damage (associated
with AD) and common memory impairment; it
includes immediate free recall exercises and
postponed free recall activities. In the case of
recall difficulty, a cue is suggested.
The CODEX test is designed to detect dementia
in elderly subjects. It is a very simple and quick
test (taking less than three minutes) and can be
performed by doctors who are not specialized in
the evaluation of memory or other cognitive
functions. This test consists of two stages: the
three-word test and simplified clock test [28] are
carried out before the MMSE (five questions of
spatial orientation). In the EVATEM study, the
three-word test, the simplified clock test and the
five spatial orientation questions were all
performed.
The test of verbal fluency measures the capacity
of a subject to generate a list of words belonging
to the same semantic category (animals), and a
list of words starting with the same letter (P),
within a time limit of two minutes. This test
assesses semantic memory and executive memory
functions. In the case of a neurodegenerative
disease, particularly in AD, semantic fluency
seems to be impaired and this may be associated
with possible damage to the semantic memory
stock [29].
2. Neuropsychological evaluation performed at MC
The cognitive tests described below were performed
routinely in MC. Episodic memory was assessed
using the following tests: a free and cued recall test
with 16 items (test adapted from Grober and
Buschke [30]), the DMS48 [31], the Signoret battery
for mnesic efficiency (BEM 144) [32] and the
Birmingham Object Recognition Battery (BORB)
[33]. Executive abilities were assessed using the
Frontal Assessment Battery (FAB) [34], Baddeley’s
dual task test [35], the Wechsler Adult Intelligence
Scale III (WAIS III) [36,37], the Trail Making Test
(TMT) [38], the STROOP test (GREFEX version)
[39] and semantic verbal and literal fluency tests
(using ‘P’ and ‘Animals’; a two minute test)[27].
Instrumental efficiency was evaluated by gestural
praxis assessment (symbolic gestures, pantomimes
and abstract gestures), the Rey complex figure [40],
the picture naming test (DO 80) [41] and the Visual
Object and Space Perception Battery (VOSP) [42].
These tests were conducted by a neuropsychologist
and lasted approximately 1.25 h.
Diagnostic criteria for MCI and AD
The chosen definition of AD was based on the criteria
of the National Institute of Neurological and Communi-
cative Diseases and Stroke and the AD and Related Dis-
orders Association (NINCDS-ADRDA) [43]; this can
diagnose AD as possible, probable or certain. The sever-
ity of dementia was based on the MMSE score [8].
Table 1 Memory complaint screening questionnaires (Q1 and Q2)
Q1: self-questionnaire Q2: questionnaire administered by the doctor
During the six last months:
1. In the last six months, have any of your close relations suggested
that you have a possible memory problem?
1. Have any of your close relations told you that you have memory problems?
2. Do you sometimes suffer from a lapse of memory during daily life? 2. Have you noticed any change in your memory?
3. Do you find it difficult to calculate? 3. Do you think that your memory now works less well than memory of other
people of age?
4. Do you have difficulties finding your words? 4. Do you find it difficult to orientate yourself, or did you ever not recognize a
place where your close relations have told you that you have been?
5. Do you have problems remembering new information? 5. Have you ever fogotten everything about an event (even if your close
relations told you about it or you saw pictures about it)?
6. Do you find it difficult to focus?
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Subjects were categorized as being in the mild stage if
their score was between 25 and 21, in moderate stage if
their score was between 20 and 10 and in the severe
stage if their score was below 10.
The diagnostic criteria for MA at a stage of dementia
were the clinical criteria for probable AD [43,44].
At the stage of pre-dementia (corresponding to the
amnestic MCI diagnosis [15,16,17,45]), diagnostic cri-
teria were the clinical criteria of the Pre-Al study and
the paraclinical criteria recently proposed for research
[46,47]. For other disorders frontotemporal lobar degen-
eration [48], lewy body dementia [49] and vascular de-
mentia [50] criteria were those referenced.
Examination procedure: baseline assessment and follow-up
1. Baseline assessment: cognitive tests at HEC
The cognitive assessments were performed by
trained physician and nurses. A guide, detailing how
to perform the cognitive tests, specified the order in
which the tests should be performed. Immediate
recall and cued free test of five words was
performed by the doctor, then an intercurrent test of
attention for about 10 minutes and finally a free and
cued delayed recall test of five words. The attention
of the subject was intentionally diverted using
several tests. For example, drawing pentagons as
part of the MMSE and a visual-construction task in
the Cognitive Assessment Battery (CAB 96) [51].
Time orientation questions (‘What day of the week
is it?’; ‘What month is it?’; ‘What year is it?’),
questions about drug intake (the number of
therapeutic classes attended, the use of a
psychotropic drug and treatment for osteoporosis),
the TUG [23] and the imagined TUG were also
used. The Instrumental Activities of Daily Living
(IADL) scale (derived from the IADL by Lawton and
Brody [21]), was used to evaluate functional
capacity. This test explores the subject’s degree of
autonomy or dependence in relation to four
practical activities of daily life (telephone use,
transportation, responsible administration of
medication and budget management). The three-
word test, the simplified clock test, the five
questions about spatial orientation and verbal
fluency tests were then performed by the nurse.
2. Baseline assessment: memory consultation at MC
An appointment for consultation at the MC was
made at the end of the periodic health examination.
If this had not been possible, the patient was
contacted by a secretary of the HEC to schedule the
appointment. The standardized biological check-up
performed at HEC included a neuropsychological
assessment, screening for syphilis, serum electrolytes
determination and serum assays of vitamin B12,
vitamin B9, albumin, pre-albumin and Thyroid
Stimulating Hormone (TSH). Depression screening
was performed using the Geriatric Depression Scale
(GDS); a 15-item scale of depressive symptomatology
suitable for elderly patients [52].
Check-ups at the University Hospital of Lyon were
supplemented by the Hamilton Anxiety Scale, a
questionnaire on therapeutic compliance and
nutritional assessment. The established diagnosis,
according to the criteria specified above, was sent to
the doctor working at the HEC so that they could
classify patients as “normal” subjects, subjects with
MCI or subjects with dementia. A MRI scan was
systematically performed at the University Hospital of
Angers. At the University Hospitals of Lyon and Saint-
Etienne, MRI scans were reserved for subjects where
anomalies were detected during the examination.
3. Follow-up at MC
Subjects of the study will be re-called one year later
(T1) at MC for a second neuropsychological check-up
using the same protocol as at T0.
Collection and data quality control
Collection and data entry are managed by the HEC of
Lyon; collected data is entered by two secretaries of the
HEC who have been trained in data management (double
input). The collection tool was developed by the Regional
Medical Service Officer (RMSO) of the Rhône-Alpes
region.
Main outcome measure
Patients will be recorded as belonging to one of three
groups: “normal”, MCI or dementia subjects. The main
outcome measure will be the diagnosis of MCI or AD and
related disorders at T0 and T1. The secondary outcome
measure will be falls at T0 and T1. A fall was defined as
an event which results in a person coming to rest uninten-
tionally on the ground, floor or at a lower level.
Statistical analysis
Baseline characteristics of the subjects (for example, age
and sex) will be described as above. Continuous vari-
ables will be summarized by the mean and standard de-
viation or the median and interquartile range (as
appropriate). Categorical variables will be summarized as
proportions of each category.
Socio-demographic and clinical comparisons will be
performed between three groups (normal, MCI and de-
mentia subjects). Group proportions will be compared
using Pearson’s chi-squared test. The means of these
groups will be compared using an Analysis of Variance
(ANOVA) with parametric and nonparametric tests,
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depending on the distribution of the variables. We will
study the relationship between the result of each cognitive
test performed at HEC and the diagnosis confirmed by the
memory consultation. A Receiver Operator Characteristic
(ROC) curve will be generated for each cognitive test,
using MCI and AD and related disorders diagnosis as ref-
erences. The optimum threshold, providing the best com-
promise between sensitivity and specificity, will therefore
be determined. Predictive and negative values, as well as
positive and negative likelihood ratios, will be calculated.
We will use a binary or multinomial logistic regression to
determine which test, or combination of cognitive tests,
are the most predictive for MCI and AD and related disor-
ders diagnosis. Models will be adjusted for potential
confounding variables.
A p value less than 0.05 will be considered as statisti-
cally significant.
Statistical analyses will be performed using SPSS (Stat-
istical Package for the Social Sciences) version 17.0 for
Windows (SPSS Inc., Chicago, Illinois, USA).
Inclusions
Inclusions at HEC took place from 15th November 2009
to 31st December 2011 (Figure 2). The one-year follow-
up will end during the first semester of 2013.
A total of 4571 elderly subjects aged 65 years or over
were eligible for research into the diagnosis of memory
complaints. Amongst those subjects, 57.5% were recruited
by the HEC of Lyon, 34.2% by the HEC of Angers and
8.3% by the HEC of Saint-Etienne.
The percentage of subjects with memory complaints,
detected using the self-administered questionnaire (Q1),
was 70% for the HEC of Angers and 59.4% for the HEC
of Saint-Etienne. At the HEC of Lyon, where memory
complaints were screened using a questionnaire admin-
istered by doctors (Q2), the percentage of complaints
was 27.5%. Cognitive tests were refused by 33.6% of
people with memory complaints. Amongst the 832 sub-
jects for whom an appointment at MC had been made,
74.5% attended a consultation. Thus, the final study
population included 620 subjects.
Angers (A)
1589 elderly subjects (ES)
Saint-Etienne (SE) 
404 elderly subjects (ES)
350 ES refuse to
participate
1094 MC (according to Q1)
A
1564 ES
Inclusion not supported 
in 32 ES
87 ES refuse to         
participate
225 MC (according to Q1)
SE
379 ES 
25 ES excluded 25 ES excluded
Lyon (L)  
3202 elderly subjects (ES)
L
2628 ES
722 MC (according to Q2) 
250 ES refuse to 
participate 
574 ES excluded 
(language barrier)
L
442 ES
832 subjects referred to a memory center
Inclusion not 
supported in 460 ES
Inclusion not 
supported in 30 ES 
Screening for memory complaint (MC)
SE
106 ES
A
284 ES
A
28  ES           
Secondary refusal
SE
1 ES             
L
61 ES
A
256 ES             
SE
105 ES           
L
381 ES         
Withdrawal
A
18 ES    
SE
13 ES    
L
90 ES +1death
620 memory consultations completed
A
238 ES
SE
92 ES
L
290 ES
(language barrier) (language barrier)
Figure 2 EVATEM study flowchart. MC: Memory Complaint, ES: elderly subjects. A: Angers, SE: Saint-Etienne, L: Lyon.
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Discussion
The EVATEM study will identify which one, or which
combination, of these studied tests are the most predictive
of MCI and AD and related disorders. This will provide a
recommendation as to which should be performed on eld-
erly patients reporting a memory complaint during a
health examination at HEC.
The age for inclusion selected for the EVATEM study
was 65 years old and more as the prevalence of AD is
low before the age of 65 years [53]. This age criterion
was also used in the PAQUID study [54] and in a three
city study [55].
HEC recruit elderly patients from those listed in the
files of the French health insurance system. Previous
studies have compared elderly individuals using HEC to
those of the general population of the same age. It ap-
pears that people over 60 years old who consult at HEC
are more likely to be young male seniors (60 to 70 years
old), living in couples, individuals with a healthy lifestyle
(lower tobacco consumption, lower alcohol consumption
and more physic activity) and those that consult more
frequently than the corresponding general population
(data unpublished, CETAF). However, it was previously
thought that the population attending HEC was not fun-
damentally different from the general population of eld-
erly persons aged over 60 years who were living at home
and not suffering from disabilities.
The fact that patients agreed to participate to a peri-
odic examination suggests that they take an interest in
their health and may therefore also be more likely to at-
tend cognitive impairment screening. Use of the Q1
questionnaire may lead to a self-selection bias associated
with the fear of diagnosis, especially if another family
member is suffering from AD. Representations of this
type of disease and people with AD in our society are
extremely negative. Consequently, patients may delay, as
long as possible, addressing the issue of a disease that
“crystallizes all the fears associated with aging” [6]. Soci-
etal representations lead to denial behavior and avoid-
ance of medical consultations as the fear of diagnosis is
associated with a set of losses including identity and dig-
nity [56,57]. The administration of Q2 by doctors from
Lyon led to a high selectivity in the screening of memory
complaints. It will be interesting to compare the diag-
nostic and predictive values of the tests that result from
these two groups.
This study, which began in late 2009, is based on the
1984 criteria for the clinical diagnosis of AD. In the re-
vised NIA-Alzheimer’s Association criteria (May 2011), a
semantic and conceptual distinction is made between
AD pathophysiological processes and the clinically ob-
servable syndromes that result (this distinction was
blurred in the 1984 criteria [58,59]). According to the re-
vised criteria, the clinical and cognitive evaluation for
MCI due to AD is almost identical to the one previously
described by Petersen et al. [59]. All patients who would
have been classified under “probable AD” by the 1984
NINCDS–ADRDA criteria would be likely to meet the
current criteria for probable AD dementia. The predict-
ive values of the three cognitive tests for the diagnosis of
a mild amnesic cognitive impairment, in turn predictive
of AD, will be analyzed.
The use of cognitive tests can be limited by language
barriers; only people with a good level of French had
been included in EVATEM. There were a particularly
high number of exclusions in Lyon and it would be in-
terested to develop a translation of the selected tests.
This study provided an opportunity for each HEC to
establish care pathways with their closest MC and for
medical and paramedical staff to be educated in the early
diagnosis of related disorders [5]. Specific training, car-
ried out by MC geriatricians, was required. This was well
received and has demonstrated that cognitive tests can
be easily integrated into a preventive consultation.
The participants of this study will be re-examined one
year after their inclusion; this will enable us to estimate the
predictive abilities of the tests to diagnose MCI and de-
mentia. The use of simple tests with good predictive abil-
ities should help guide patients from centers of prevention
to MC for early medical and behavioral care management.
Further research projects are planned using the
EVATEM database. These include studying the relation-
ships between insecurity and memory complaints, cogni-
tion and anxiety-depression, cognition and walking, and
cognition and vitamin D levels.
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